Small molecule inhibitors of SARS-CoV-2 viral replication and uses thereof
AssigneeArizona Board of Regents on Behalf of the University of Arizona
InventorsJun Wang, Chunlong Ma
Life of this patent
Estimating the term…
Abstract
This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replication and/or SARS-CoV-2 related viral 3CL protease (Mpro) activity. The invention further relates to methods of treating and/or ameliorating symptoms related to conditions caused by the SARS-CoV-2 virus (e.g., COVID-19), comprising administering to a subject (e.g., a human patient) a composition comprising one or more pharmaceutical agents which function as inhibitors of SARS-CoV-2 viral replication and/or inhibitors of SARS-CoV-2 related Mpro activity.
Claims10
A compound encompassed within Formulas I:
- including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof,
- wherein R1 is selected from the group consisting of hydrogen, methyl,
- wherein R2 is selected from the group consisting of hydrogen,
- wherein R3 is selected from the group consisting of hydrogen,
- wherein R4 is selected from the group consisting of hydrogen, methyl,
- wherein if R1 is methyl, R2 is
- and R3 is
- then R4 cannot be
- wherein if R4 is methyl, R2 is
- and R3 is
- then R1 cannot be
- Wherein if R4 is
- then R1 cannot be
- Wherein if R1 is
- then R4 cannot be
Dependencies are inferred from the claim text.